Development of Cyclized L-RNA Aptamer and Application Thereof
Knowledge Transfer Office, City University of Hong Kong
KTO aspires to become the gateway for easy access to the intellectual resources nurtured by the CityU.
Over the past few decades, antibodies have been the most popular products for molecular recognition of bio-targets. They are used across broad domains, including life and health sciences, as well as in clinical settings. The estimated market for antibodies was roughly 85 billion USD in 2015 and is expected to grow to 140 billion USD in 2024.?
Given the widespread use of antibodies, there is an opportunity to develop more efficient alternatives. Aptamer, an emerging tool, can also tap into the same domains as antibodies but as a better alternative. Compared with antibodies, aptamer can typically be generated in weeks instead of months, and can be stored and applied in a broader range of conditions. L-RNA aptamer (Spigelmer), one of the most advanced and promising technologies to generate nuclease-resistant aptamer, is expected to quickly penetrate into the existing antibody and aptamer market. Thus, the opportunity exists to provide a universal, simple, and robust strategy for L-RNA oligos cyclization.
To uncover this invention, please visit our IP Portal.